CW August 2005
Volume 14Issue Number 8 August 2005 ISSN 10593802 A Broad-Spectrum Anticancer AgentPhase I/II clinical trials are being conducted to assess the anticancer effect of a telomerase inhibitor, GRN163L.
Go to Previous Page Go to Next Page Source & Additional Reading For more information about this initial Phase I/II trial, visit the U.S. National Library of Medicine website at http://www.ClinicalTrials.gov to access a brief study synopsis. A link to this site is also provided on Geron?s website at http://www.geron.com. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW August 2005Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
